Phylogica Ltd – European Patent Granted Covering Phylomer Peptides For Ischemia

PERTH, AUSTRALIA: April 24, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, has been granted a new European patent (no. 1793841) entitled: ‘Peptide inhibitors of c-­‐Jun dimerization and uses thereof’. This international patent (PCT/AU2005/001255) covers the Company’s lead Phylomer peptides targeting the AP-­‐1 pathway, which is a crucial mediator of inflammation and cell death in multiple diseases.

The AP-­‐1 pathway plays a critical role in neuronal cell death caused by stroke and traumatic brain injury, and lung inflammation resulting from acute respiratory distress syndrome (ARDS) and septic shock. The family of Phylomer peptides has demonstrated efficacy in multiple preclinical models for stroke, traumatic brain injury and ARDS. The granted claims of the patent cover any use of these Phylomers in the treatment of ischemic disease, including important clinical settings such as stroke, traumatic brain injury and reperfusion injury of liver, heart and blood vessels following transplantation. Ischemia, or insufficient blood supply is a critical cause of inflammation and cell death. Often this damage is exacerbated when blood supply returns to the vessel or organ. The peptides covered by this patent are active in this pathway and help to reduce the collateral damage to tissue.

To read the full ASX announcement please download the document below.